#China #Shenzhen #MGI Tech #DNBSEQ-T1+ #CE Mark

MGI Tech's DNBSEQ-T1+ Sequencer Receives CE Mark

In a significant stride for genomic research, MGI Tech Co., Ltd., a leader in life sciences innovation, has announced that its latest mid-throughput sequencer, the DNBSEQ-T1+, has successfully attained the CE mark within the EU certification framework. This milestone not only facilitates its entry into the European market but also emphasizes its extensive capabilities for both research and clinical applications, heralding a new era in genomic technologies.

Advanced Technology Behind DNBSEQ-T1+

Launched at the recent AGBT 2025, the T1+ stands out as a cutting-edge benchtop genetic sequencer that delivers impressive mid-throughput sequencing capabilities. The system is engineered to perform a paired-end 150 sequencing workflow, achieving remarkable Q40 accuracy within a mere 24 hours. Such speed places it amongst the fastest mid-throughput sequencers worldwide, offering users an industrial-leading sequencing speed that meets the demands of modern research.

This innovative sequencer is available in three flow cell formats, boasting two to four addressable lanes for enhanced flexibility and throughput. The T1+ offers data outputs ranging from a substantial 25 to 1,200 Gb, equipping researchers with the ability to carry out diverse independent experiments on a single platform. This versatility significantly enhances laboratory efficiency, allowing researchers to adapt the T1+ to various experimental needs seamlessly.

Moreover, integrating auto-DNB making and loading systems along with a built-in bioinformatics module further simplifies the user experience. These innovations are designed to optimize workflow, allowing for a smoother sequencing journey that greatly increases productivity across various research initiatives.

Implications for Research and Clinical Applications

Duncan Yu, President of MGI, expressed the significance of this CE marking, stating, "It is a strong affirmation that the T1+ complies fully with EU standards and regulations for research and clinical applications." He emphasized that the T1+ is expected to catalyze advancements in genomics, enabling EU researchers and clinicians to leverage its precision and efficiency to make strides in fields like precision medicine and oncology.

Since its debut at the European Society of Human Genetics (ESHG) exhibition, the DNBSEQ-T1+ has sparked considerable interest. Attendees were keen to experience firsthand the technological advancements and potential applications of the T1+ in real-world settings. This enthusiasm highlights the T1+ as a pivotal tool for enhancing genomic research and clinical applications across Europe.

About MGI Tech

Established in 2016, MGI Tech Co., Ltd. has made its mark as a frontrunner in the life sciences sector. The company is committed to developing core tools and technologies that enhance innovation, focusing on the research and development, manufacturing, and sales of advanced instruments and reagents within the life science and biotechnology domains. MGI is recognized for delivering a complete spectrum of digital tools and systems that cater to precision medicine, healthcare, and various other industries.

With a growing global footprint, MGI serves clients across six continents, continuously expanding its research, manufacturing, training, and after-sales service capabilities. MGI stands out as one of the few organizations capable of independently developing clinical-grade gene sequencers with diverse throughput options, ranging from gigabases (Gb) to terabases (Tb), ensuring it remains at the forefront of shaping the future of life sciences.

For further information, please visit MGI's official website or check them out on LinkedIn, X, and YouTube.